content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on April 4, 2025</B></P>
  
  <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Registration No. 333-______</B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM S-8&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REGISTRATION STATEMENT</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDER THE SECURITIES ACT OF 1933</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Altamira Therapeutics Ltd.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Bermuda</B></FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">incorporation or organization)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Clarendon House</B></FONT></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>2 Church Street</B></FONT></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Hamilton HM 11, Bermuda</B></FONT></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></P>
  
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Altamira Therapeutics Ltd. Equity Incentive
  Plan, as amended</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Thomas Meyer, PhD</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>President</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Altamira Therapeutics,
  Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>254 Chapman Rd, Ste 208
  #15392</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Newark, DE 19702</b></p>
  
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></B>(Name
  and address of agent for service)</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(302) 200-8095</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Telephone number, including area code, of agent
  for service)</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Copies to:</I></B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>W. David Mannheim</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Michael K. Bradshaw, Jr.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nelson Mullins Riley
  &amp; Scarborough LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>301 Hillsborough Street, Suite 1400</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Raleigh, NC 27603</B></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Raleigh, NC 27603</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: (919) 329-3800 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Indicate by check mark whether
  the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
  growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
  company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%; font-size: 10pt; text-align: justify">Large accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="width: 40%; font-size: 10pt; text-align: justify">Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: justify">Non-accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
      <TD STYLE="font-size: 10pt; text-align: justify">Smaller reporting company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 1; Options: NewSection -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.2pt">Pursuant to General Instruction
  E to Form S-8 under the Securities Act of 1933, as amended, this Registration Statement is filed by Altamira Therapeutics Ltd. (the &ldquo;Company&rdquo;)
  for the purpose of registering additional common shares of the Company, par value USD 0.002 per share (the &ldquo;Common Shares&rdquo;)
  under the Altamira Therapeutics Ltd. Equity Incentive Plan, as amended (the &ldquo;EIP&rdquo;). This Registration Statement registers
  an aggregate of 1,696,687 additional Common Shares available for issuance under the EIP pursuant to the approval by the board of directors
  of the Company (the &ldquo;Board&rdquo;) on March 27, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The Common Shares registered pursuant to this
  Registration Statement are of the same class of securities as the 300,000 Common Shares registered for issuance under EIP pursuant to
  the currently effective Registration Statement on Form S-8 (Registration No. 333-278595) filed on April 10, 2024, the 3,000 Common Shares
  registered for issuance under the EIP pursuant to the currently effective Registration Statement on Form S-8 (Registration No. 333-252141)
  filed on January 15, 2021 and the 750 Common Shares registered for issuance under the EIP pursuant to the currently effective Registration
  Statement on Form S-8 (Registration No. 333-232735) filed on July 19, 2019. The information contained in the Company&rsquo;s Registration
  Statements on Form S-8 (Registration Nos. 333-278595, 333-252141 and 333-232735) are hereby incorporated by reference pursuant to General
  Instruction E of Form S-8.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">The information specified in
  Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under
  the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the introductory note to Part I of Form S-8. The documents
  containing the information specified in Part I of Form S-8 will be delivered to the participants in the EIP covered by this Registration
  Statement as specified by Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the
  Securities and Exchange Commission (the &ldquo;Commission&rdquo;) either as part of this Registration Statement or as a prospectus or
  prospectus supplement pursuant to Rule 424 under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
  <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">our Annual Report on Form
  20-F for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
  on <a href="https://www.sec.gov/Archives/edgar/data/1601936/000121390024031734/ea0201981-20f_altamirather.htm">April 10, 2024</a>, as amended on <a href="https://www.sec.gov/Archives/edgar/data/1601936/000121390024034940/ea0204302-20fa1_altamira.htm">April
  22, 2024</a> and <a href="https://www.sec.gov/Archives/edgar/data/1601936/000121390024057548/ea0208669-20fa2_altamira.htm">July 1, 2024</a>;</td>
  </tr></table>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <td style="width: 0.25in"></TD><td style="width: 0.25in; text-align: left">(b)</TD><td style="text-align: justify">our Reports on Form 6-K furnished on <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024004886/ea191765-6k_altamira.htm">January
  19, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024004906/ea191800-6k_altamira.htm">January 19, 2024</A>,
  <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024044325/ea0206215-6k_altamira.htm">May 16, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024080300/ea0215114-6k_altamira.htm">September 19, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024081199/ea0213577-6k_altamira.htm">September 24, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024085537/ea0216654-6k_altamira.htm">October 4, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea0225514-6k_altamira.htm">December 20, 2024</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390025022236/ea0233793-6k_altamira.htm">March 10, 2025</A>; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <td style="width: 0.25in"></TD><td style="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><td style="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our Common
  Shares contained our Report on </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1601936/000095010319003452/dp103770_8k12g3.htm"><FONT STYLE="font-size: 10pt">Form
  6-K</FONT> </A><FONT STYLE="font-size: 10pt">furnished on March 18, 2019, including any subsequent amendment or reports filed for the
  purpose of updating such description.</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  relation to the description of our Common Shares, please note the following change applies to &ldquo;Item 10&mdash;Additional Information&mdash;B.
  Memorandum and articles of association&mdash;Bermuda Description of Share Capital&mdash;Exchange Controls&rdquo; in the Company&rsquo;s
  Annual Report on Form 20-F for the year ended December 31, 2018, filed with the SEC on March 2019, which is incorporated by reference
  in the Report on Form 6-K furnished on March 18, 2019, as the Common Shares are no longer traded on the Nasdaq Capital Market, or the
  Nasdaq:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;<B>Exchange
  Controls</B></I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
  permission of the Bermuda Monetary Authority is required, under the provisions of the Exchange Control Act 1972 and related regulations,
  for all issuances and transfers of shares (which includes the common shares of the Company) of Bermuda companies to or from a non-resident
  of Bermuda for exchange control purposes, other than in cases where the Bermuda Monetary Authority has granted a general permission.
  </I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
  had previously received consent under the Exchange Control Act 1972 from the Bermuda Monetary Authority for the issue and transfer of
  the common shares to and between non-residents of Bermuda for exchange control purposes provided our shares remained listed on an appointed
  stock exchange, which includes the Nasdaq Capital Market. </I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>As
  our common shares are no longer listed on the Nasdaq Capital Market, we have received consent under the Exchange Control Act 1972 from
  the Bermuda Monetary Authority for the issuance of the common shares, pursuant to the EIP, to non-residents of Bermuda for exchange control
  purposes, without the approval of the Bermuda Monetary Authority. In granting such consent the Bermuda Monetary Authority accepts no
  responsibility for our financial soundness or the correctness of any of the statements made or opinions expressed in this Registration
  Statement. </I>&rdquo;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">All subsequent annual reports
  on Form 20-F filed by us and all subsequent reports on Form 6-K filed by us that are identified by us as being incorporated by reference
  shall be deemed to be incorporated by reference into this Registration Statement and shall be deemed to be a part hereof after the date
  of this Registration Statement but before the termination of the offering hereunder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">In addition, all documents
  filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
  Act&rdquo;) subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration
  Statement that indicates that all securities offered hereunder have been sold or that deregisters all such securities then remaining unsold
  shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of
  such documents, provided, that any report on Form 6-K of the Registrant hereafter furnished to the Commission pursuant to the Exchange
  Act shall be incorporated by reference into this Registration Statement only if and to the extent provided in such document.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Any statement contained in
  any document incorporated or deemed to be incorporated by reference into this Registration Statement shall be deemed to be modified or
  superseded for purposes thereof to the extent that a statement contained therein or in any other subsequently filed document that is also
  incorporated or deemed to be incorporated therein by reference modifies or supersedes such statement. Any such statement so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; font-size: 10pt; text-align: left"><B>Exhibit <BR> Number</B></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 90%">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">4.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390023018094/ea174703ex3-1_altamira.htm"><FONT STYLE="font-size: 10pt">Memorandum of Continuance and Corporate Actions of the registrant (incorporated herein by reference to exhibit 3.1 of the Altamira</FONT></A> <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390023018094/ea174703ex3-1_altamira.htm"><FONT STYLE="font-size: 10pt">Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on March 7, 2023)</FONT></A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">4.2</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024071896/ea021179401ex3-2_altamira.htm">Extract of Directors&rsquo; Unanimous Written Resolutions, dated November 28, 2023 (incorporated herein by reference to exhibit 3.2 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-281724) filed with the Commission on August 22, 2024)</A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">4.3</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390024071896/ea021179401ex3-3_altamira.htm">Certificate of Deposit of Memorandum of Increase of Share Capital, dated May 30, 2024 (incorporated herein by reference to exhibit 3.3 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-281724) filed with the Commission on August 22, 2024)</A></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">4.4</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390023012310/ea171207ex3-2_altamirathe.htm"><FONT STYLE="font-size: 10pt">Bye-laws of the Registrant (incorporated herein by reference to exhibit 3.2 of the Altamira Therapeutics Ltd. registration statement on Form</FONT></A> <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390023012310/ea171207ex3-2_altamirathe.htm"><FONT STYLE="font-size: 10pt">F-1 (Registration No. 333-269823) filed with the Commission on February 16, 2023)</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">5.1*</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="ea023652601ex5-1_altamira.htm">Opinion of Conyers Dill &amp; Pearman Limited, Bermuda counsel to the Registrant (filed herewith)</a></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">23.1*</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="ea023652601ex23-1_altamira.htm">Consent of BDO AG (filed herewith)</a></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">23.2*</TD>
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="ea023652601ex23-2_altamira.htm">Consent of Deloitte AG (filed herewith)</a></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">23.3*</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="ea023652601ex5-1_altamira.htm">Consent of Conyers Dill &amp; Pearman Limited, Bermuda counsel to the Registrant (included in Exhibit 5.1)</a></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">24.1*</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="#poa_001">Power of Attorney (included in the signature page hereof)</a></TD></TR>
    <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">99.1</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390019013206/fs82019ex99-1_aurismedical.htm"><FONT STYLE="font-size: 10pt">Altamira Therapeutics Ltd. Equity Incentive Plan, as amended (incorporated herein by reference to exhibit 99.1 of the Auris Medical</FONT></A> <A HREF="https://www.sec.gov/Archives/edgar/data/1601936/000121390019013206/fs82019ex99-1_aurismedical.htm"><FONT STYLE="font-size: 10pt">Holding Ltd. Registration Statement on Form S-8 filed with the Commission on July 19, 2019)</FONT></A></TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">107*</TD>
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"><a href="ea023652601ex-fee_altamira.htm">Filing Fee Table</a></TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned Registrant hereby
  undertakes:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To file, during any period in
  which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To include any prospectus required
  by Section 10(a)(3) of the Securities Act;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To reflect in the prospectus
  any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding
  the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
  that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
  form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
  no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Filing Fee Tables&rdquo; or &ldquo;Calculation
  of Registration Fee&rdquo; table, as applicable, in the effective registration statement; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To include any material information
  with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information
  in the Registration Statement;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><I>provided, however</I>, that paragraphs
  (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange
  Act that are incorporated by reference in this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining
  any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
  to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering
  thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To remove from registration by
  means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned Registrant
  hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual
  report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s
  annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be
  deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant
  to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><a name="poa_001"></a>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Hamilton, Bermuda, on April 4, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Altamira Therapeutics Ltd.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas Meyer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
      <TD STYLE="width: 31%"> <FONT STYLE="font-size: 10pt">Thomas Meyer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
      <TD> <FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">KNOW ALL PERSONS BY THESE
  PRESENTS, that each person whose signature appears below hereby constitutes and appoints Thomas Meyer and Marcel Gremaud and each of them,
  individually, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in
  his name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and
  on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and
  registrations filed pursuant to Rule 462 under the U.S. Securities Act of 1933, and to file the same, with all exhibits thereto, and other
  documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full
  power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
  to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
  or either of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates
  indicated:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Thomas Meyer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Thomas Meyer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Marcel Gremaud</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Marcel Gremaud</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Mats Blom</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Mats Blom</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Alain Munoz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Alain Munoz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Dominik Lysek</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Dominik Lysek</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    </TABLE>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZED REPRESENTATIVE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of Section 6(a) of
  the Securities Act of 1933, the undersigned has signed this Registration Statement on Form S-8, solely in the capacity of the duly authorized
  representative of Altamira Therapeutics Ltd. in the United States, on April 4, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Altamira Therapeutics, Inc.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas Meyer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
      <TD STYLE="width: 31%"> <FONT STYLE="font-size: 10pt">Thomas Meyer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
      <TD> <FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 8; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0236526-s8_altamira.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 54001}]
metadata_filer: {"company-data": {"conformed-name": "Altamira Therapeutics Ltd.", "cik": "0001601936", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "ein": "000000000", "state-of-incorporation": "D0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-286392", "film-number": "25815191"}, "business-address": {"street1": "CLARENDON HOUSE", "street2": "2 CHURCH STREET", "city": "HAMILTON HM 11", "state": "D0", "zip": "00000", "phone": "41 (0) 41 729 71 94"}, "mail-address": {"street1": "CLARENDON HOUSE", "street2": "2 CHURCH STREET", "city": "HAMILTON HM 11", "state": "D0", "zip": "00000"}, "former-company": [{"former-conformed-name": "Auris Medical Holding Ltd.", "date-changed": "20190318"}, {"former-conformed-name": "Auris Medical Holding AG", "date-changed": "20190314"}, {"former-conformed-name": "Auris Medical Holding Ltd.", "date-changed": "20190312"}]}
text: As filed with the Securities and Exchange Commission on April 4, 2025
  Registration No. 333-______
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER THE SECURITIES ACT OF 1933
  Altamira Therapeutics Ltd.
  (Exact name of registrant as specified in its charter)
  Bermuda
  Not Applicable
  (State or other jurisdiction of
  (I.R.S. Employer
  incorporation or organization)
  Identification No.)
  Clarendon House
  2 Church Street
  Hamilton HM 11, Bermuda
  (Address of Principal Executive Offices)
  Altamira Therapeutics Ltd. Equity Incentive
  Plan, as amended
  (Full title of the plan)
  Thomas Meyer, PhD
  President
  Altamira Therapeutics,
  Inc.
  254 Chapman Rd, Ste 208
  #15392
  Newark, DE 19702
  (Name
  and address of agent for service)
  (302) 200-8095
  (Telephone number, including area code, of agent
  for service)
  Copies to:
  W. David Mannheim
  Michael K. Bradshaw, Jr.
  Nelson Mullins Riley
  & Scarborough LLP
  301 Hillsborough Street, Suite 1400
  Raleigh, NC 27603
  Raleigh, NC 27603
  Tel: (919) 329-3800
  Indicate by check mark whether
  the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
  growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
  company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☐
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☐
  EXPLANATORY NOTE
  Pursuant to General Instruction
  E to Form S-8 under the Securities Act of 1933, as amended, this Registration Statement is filed by Altamira Therapeutics Ltd. (the "Company")
  for the purpose of registering additional common shares of the Company, par value USD 0.002 per share (the "Common Shares")
  under the Altamira Therapeutics Ltd. Equity Incentive Plan, as amended (the "EIP"). This Registration Statement registers
  an aggregate of 1,696,687 additional Common Shares available for issuance under the EIP pursuant to the approval by the board of directors
  of the Company (the "Board") on March 27, 2025.
  The Common Shares registered pursuant to this
  Registration Statement are of the same class of securities as the 300,000 Common Shares registered for issuance under EIP pursuant to
  the currently effective Registration Statement on Form S-8 (Registration No. 333-278595) filed on April 10, 2024, the 3,000 Common Shares
  registered for issuance under the EIP pursuant to the currently effective Registration Statement on Form S-8 (Registration No. 333-252141)
  filed on January 15, 2021 and the 750 Common Shares registered for issuance under the EIP pursuant to the currently effective Registration
  Statement on Form S-8 (Registration No. 333-232735) filed on July 19, 2019. The information contained in the Company's Registration
  Statements on Form S-8 (Registration Nos. 333-278595, 333-252141 and 333-232735) are hereby incorporated by reference pursuant to General
  Instruction E of Form S-8.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  The information specified in
  Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under
  the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents
  containing the information specified in Part I of Form S-8 will be delivered to the participants in the EIP covered by this Registration
  Statement as specified by Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the
  Securities and Exchange Commission (the "Commission") either as part of this Registration Statement or as a prospectus or
  prospectus supplement pursuant to Rule 424 under the Securities Act.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  (a)
  our Annual Report on Form
  20-F for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "Commission")
  on
  April 10, 2024
  , as amended on
  April
  22, 2024
  and
  July 1, 2024
  ;
  (b)
  our Reports on Form 6-K furnished on
  January
  19, 2024
  ,
  January 19, 2024
  ,
  May 16, 2024
  ,
  September 19, 2024
  ,
  September 24, 2024
  ,
  October 4, 2024
  ,
  December 20, 2024
  and
  March 10, 2025
  ; and
  (c)
  the description of our Common
  Shares contained our Report on
  Form
  6-K
  furnished on March 18, 2019, including any subsequent amendment or reports filed for the
  purpose of updating such description.
  In
  relation to the description of our Common Shares, please note the following change applies to "Item 10—Additional Information—B.
  Memorandum and articles of association—Bermuda Description of Share Capital—Exchange Controls" in the Company's
  Annual Report on Form 20-F for the year ended December 31, 2018, filed with the SEC on March 2019, which is incorporated by reference
  in the Report on Form 6-K furnished on March 18, 2019, as the Common Shares are no longer traded on the Nasdaq Capital Market, or the
  Nasdaq:
  "
  Exchange
  Controls
  The
  permission of the Bermuda Monetary Authority is required, under the provisions of the Exchange Control Act 1972 and related regulations,
  for all issuances and transfers of shares (which includes the common shares of the Company) of Bermuda companies to or from a non-resident
  of Bermuda for exchange control purposes, other than in cases where the Bermuda Monetary Authority has granted a general permission.
  We
  had previously received consent under the Exchange Control Act 1972 from the Bermuda Monetary Authority for the issue and transfer of
  the common shares to and between non-residents of Bermuda for exchange control purposes provided our shares remained listed on an appointed
  stock exchange, which includes the Nasdaq Capital Market.
  As
  our common shares are no longer listed on the Nasdaq Capital Market, we have received consent under the Exchange Control Act 1972 from
  the Bermuda Monetary Authority for the issuance of the common shares, pursuant to the EIP, to non-residents of Bermuda for exchange control
  purposes, without the approval of the Bermuda Monetary Authority. In granting such consent the Bermuda Monetary Authority accepts no
  responsibility for our financial soundness or the correctness of any of the statements made or opinions expressed in this Registration
  Statement.
  "
  All subsequent annual reports
  on Form 20-F filed by us and all subsequent reports on Form 6-K filed by us that are identified by us as being incorporated by reference
  shall be deemed to be incorporated by reference into this Registration Statement and shall be deemed to be a part hereof after the date
  of this Registration Statement but before the termination of the offering hereunder.
  II-
  1
  In addition, all documents
  filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange
  Act") subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration
  Statement that indicates that all securities offered hereunder have been sold or that deregisters all such securities then remaining unsold
  shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of
  such documents, provided, that any report on Form 6-K of the Registrant hereafter furnished to the Commission pursuant to the Exchange
  Act shall be incorporated by reference into this Registration Statement only if and to the extent provided in such document.
  Any statement contained in
  any document incorporated or deemed to be incorporated by reference into this Registration Statement shall be deemed to be modified or
  superseded for purposes thereof to the extent that a statement contained therein or in any other subsequently filed document that is also
  incorporated or deemed to be incorporated therein by reference modifies or supersedes such statement. Any such statement so modified or
  superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  Item 8. Exhibits.
  Exhibit
  Number
  4.1
  Memorandum of Continuance and Corporate Actions of the registrant (incorporated herein by reference to exhibit 3.1 of the Altamira
  Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-269823) filed with the Commission on March 7, 2023)
  4.2
  Extract of Directors' Unanimous Written Resolutions, dated November 28, 2023 (incorporated herein by reference to exhibit 3.2 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-281724) filed with the Commission on August 22, 2024)
  4.3
  Certificate of Deposit of Memorandum of Increase of Share Capital, dated May 30, 2024 (incorporated herein by reference to exhibit 3.3 of the Altamira Therapeutics Ltd. registration statement on Form F-1 (Registration No. 333-281724) filed with the Commission on August 22, 2024)
  4.4
  Bye-laws of the Registrant (incorporated herein by reference to exhibit 3.2 of the Altamira Therapeutics Ltd. registration statement on Form
  F-1 (Registration No. 333-269823) filed with the Commission on February 16, 2023)
  5.1*
  Opinion of Conyers Dill & Pearman Limited, Bermuda counsel to the Registrant (filed herewith)
  23.1*
  Consent of BDO AG (filed herewith)
  23.2*
  Consent of Deloitte AG (filed herewith)
  23.3*
  Consent of Conyers Dill & Pearman Limited, Bermuda counsel to the Registrant (included in Exhibit 5.1)
  24.1*
  Power of Attorney (included in the signature page hereof)
  99.1
  Altamira Therapeutics Ltd. Equity Incentive Plan, as amended (incorporated herein by reference to exhibit 99.1 of the Auris Medical
  Holding Ltd. Registration Statement on Form S-8 filed with the Commission on July 19, 2019)
  107*
  Filing Fee Table
  *
  Filed herewith.
  II-
  2
  Item 9. Undertakings.
  (a)
  The undersigned Registrant hereby
  undertakes:
  (1)
  To file, during any period in
  which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To include any prospectus required
  by Section 10(a)(3) of the Securities Act;
  (ii)
  To reflect in the prospectus
  any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding
  the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
  that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
  form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
  no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation
  of Registration Fee" table, as applicable, in the effective registration statement; and
  (iii)
  To include any material information
  with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information
  in the Registration Statement;
  provided, however
  , that paragraphs
  (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange
  Act that are incorporated by reference in this Registration Statement.
  (2)
  That, for the purpose of determining
  any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
  to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
  bona fide
  offering
  thereof.
  (3)
  To remove from registration by
  means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
  (b)
  The undersigned Registrant
  hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual
  report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's
  annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be
  deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial
  bona fide
  offering thereof.
  (c)
  Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant
  to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
  is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
  person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
  public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  3
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in Hamilton, Bermuda, on April 4, 2025.
  Altamira Therapeutics Ltd.
  By:
  /s/ Thomas Meyer
  Name:
  Thomas Meyer
  Title:
  Chief Executive Officer
  KNOW ALL PERSONS BY THESE
  PRESENTS, that each person whose signature appears below hereby constitutes and appoints Thomas Meyer and Marcel Gremaud and each of them,
  individually, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in
  his name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and
  on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and
  registrations filed pursuant to Rule 462 under the U.S. Securities Act of 1933, and to file the same, with all exhibits thereto, and other
  documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full
  power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
  to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
  or either of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates
  indicated:
  Name
  Title
  Date
  /s/ Thomas Meyer
  Chief Executive Officer and Director
  April 4, 2025
  Thomas Meyer
  (Principal Executive Officer)
  /s/ Marcel Gremaud
  Chief Financial Officer
  April 4, 2025
  Marcel Gremaud
  (Principal Financial Officer and Principal Accounting Officer)
  /s/ Mats Blom
  Director
  April 4, 2025
  Mats Blom
  /s/ Alain Munoz
  Director
  April 4, 2025
  Alain Munoz
  /s/ Dominik Lysek
  Director
  April 4, 2025
  Dominik Lysek
  II-
  4
  AUTHORIZED REPRESENTATIVE
  Pursuant to the requirements of Section 6(a) of
  the Securities Act of 1933, the undersigned has signed this Registration Statement on Form S-8, solely in the capacity of the duly authorized
  representative of Altamira Therapeutics Ltd. in the United States, on April 4, 2025.
  Altamira Therapeutics, Inc.
  By:
  /s/ Thomas Meyer
  Name:
  Thomas Meyer
  Title:
  President
  II-
  5